Merck & Co plans to launch a tender offer for the remaining 49% of Banyu Pharmaceutical shares for US$1.2 B (US$11.75 per share). The offer will be made by Merck’ subsidiary, MSD (Japan) Co and is conditional on Merck’s receipt of at least 75.6 M shares.